- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05135559
Une étude de recherche sur l'efficacité du concizumab pour vous si vous souffrez d'hémophilie A ou B avec ou sans inhibiteurs (Explorer10)
Étude ouverte portant sur l'efficacité, l'innocuité et la pharmacocinétique de la prophylaxie au concizumab chez les enfants de moins de 12 ans atteints d'hémophilie A ou B avec ou sans inhibiteurs
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
Participants will have to inject the study medicine every day under the skin with a pen-injector.
The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Accès étendu
Contacts et emplacements
Lieux d'étude
-
-
Gauteng
-
Parktown, Johannesburg, Gauteng, Afrique du Sud, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Algiers, Algérie, 16000
- Haematology and Blood Bank Department
-
Constantine, Algérie, 25000
- CHU Constantine BEN BADIS/ Hematology department
-
-
-
-
-
Banja Luka, Bosnie Herzégovine, 78000
- University Clinical Center of Republic Srpska (545)
-
Tuzla, Bosnie Herzégovine, 75000
- University Clinical Centre Tuzla
-
-
-
-
-
Plovdiv, Bulgarie, 4002
- UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
-
Sofia, Bulgarie, 1527
- UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
-
Varna, Bulgarie, 9010
- UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- BC Children's Hospital
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital
-
-
-
-
-
Barcelona, Espagne, 08035
- Hospital Vall d'Hebron
-
Madrid, Espagne, 28046
- Hospital Universitario La Paz
-
Málaga, Espagne, 29009
- Hospital Regional Universitario de Málaga
-
-
Murcia
-
El Palmar, Murcia, Espagne, 30120
- Hospital Virgen de la Arrixaca - Hematología
-
-
-
-
-
Tallinn, Estonie, 13419
- Tallinn Children's Hospital
-
-
-
-
-
Chambéry, France, 73000
- Centre Hospitalier Metropole Savoie
-
Le Kremlin-Bicêtre, France, 94275
- Ap-Hp-Hopital de Bicetre-1
-
Paris, France, 75015
- AP-HP-HOPITAL NECKER_Service d'hématologie
-
-
-
-
-
Athens, Grèce, GR-11527
- Aghia Sophia Childrens' Hospital
-
Thessaloniki, Grèce, GR 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
Thessaloniki, Grèce, 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
-
-
-
Assam
-
Guwahati, Assam, Inde, 781032
- Guwahati Medical College
-
-
Gujarat
-
Surat, Gujarat, Inde, 395002
- Nirmal Hospital Pvt. Ltd.
-
-
Maharashtra
-
Kolhāpur, Maharashtra, Inde, 416005
- SSSH_Dept. of Clinical Haematology & Haemato Oncology
-
Mumbai, Maharashtra, Inde, 400012
- Seth GS Medical College & KEM Hospital
-
Mumbai, Maharashtra, Inde, 400022
- K.J Somaiya Hospital and Research Centre
-
Mumbai, Maharashtra, Inde, 400066
- MCGM - Comprehensive Thalassemia Care
-
Pune, Maharashtra, Inde, 411004
- Sahyadri Super Speciality Hospital
-
-
Odisha
-
Cuttack, Odisha, Inde, 753007
- S.C.B. Medical College
-
-
Rajasthan
-
Jaipur, Rajasthan, Inde, 302004
- J K Lon Hospital
-
-
Uttar Pradesh
-
Noida, Uttar Pradesh, Inde, 201303
- Post Graduate Institute of Child Health
-
-
Uttart Pradesh
-
Lucknow, Uttart Pradesh, Inde, 226014
- SGPGI
-
-
-
-
-
Catania, Italie, 95123
- A.O.U policlinico "G. Rodolico-San Marco"
-
Florence, Italie, 50134
- Dipartimento di Ematologia Univ. Firenze
-
Padova, Italie, 35128
- Azienda Ospedaliera di Padova _
-
Parma, Italie, 43126
- Azienda Ospedaliera-Universitaria Parma
-
-
-
-
-
Kanagawa, Japon, 216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Saitama, Japon, 330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
-
-
-
-
Beirut, Liban, 961
- Saint George Hospital University Medical Center
-
Tripoli, Liban, 1434
- Hospital Nini
-
-
-
-
-
Vilnius, Lituanie, LT-08406
- Centre of Oncology and Hematology, Vilnius University
-
-
-
-
-
Skopje, Macédoine du Nord, 1000
- PHI University Clinic for Children's Diseases Skopje
-
-
-
-
Kuala Lumpur
-
Kampung Baru, Kuala Lumpur, Malaisie, 50300
- Hospital Tunku Azizah
-
-
Pulau Pinang
-
George Town, Pulau Pinang, Malaisie, 10450
- Hospital Pulau Pinang
-
-
Sarawak
-
Kuching, Sarawak, Malaisie, 93586
- Sarawak General Hospital
-
-
Terengganu
-
Kuala Terengganu, Terengganu, Malaisie, 20400
- Hospital Sultanah Nur Zahirah
-
-
-
-
-
Oslo, Norvège, 0372
- Klinisk forskningspost
-
-
-
-
-
Gdansk, Pologne, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Lublin, Pologne, 20-093
- Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
-
Warsaw, Pologne, 02-091
- Uniwersyteckie Centrum Kliniczne WUM
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Pologne, 50-556
- Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
-
-
-
-
-
Bucharest, Roumanie, 022328
- Clinic of Haematology, Fundeni Clinical Institute
-
Cluj-Napoca, Roumanie, 400177
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
-
Oradea, Roumanie, 410469
- Spitalul Clinic Judetean De Urgenta Bihor
-
-
-
-
-
Birmingham, Royaume-Uni, B4 6NH
- Birmingham Children's Hospital
-
Bristol, Royaume-Uni, BS2 8BJ
- University Hospitals Bristol & Weston NHS Foundation Trust
-
London, Royaume-Uni, WC1N 3HR
- Great Ormond Street Hospital for Children
-
London, Royaume-Uni, SE1 7EH
- Evelina London Children's Hospital - Haemophilia
-
-
-
-
-
Gothenburg, Suède, 413 46
- Sahlgrenska US - Koagulationscentrum
-
-
-
-
-
Bangkok, Thaïlande, 10400
- Ramathibodi Hospital
-
Bangkok, Thaïlande, 10330
- King Chulalongkorn Memorial Hospital_Bangkok_0
-
Bangkok, Thaïlande, 10700
- Siriraj Hospital - Hematology and Oncology
-
Bangkok, Thaïlande, 10330
- King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
-
-
Mueang Distirct,
-
Ubon Ratchathani, Mueang Distirct,, Thaïlande, 34000
- Sunpasitthiprasong Hospital_Pediatrics Department
-
-
-
-
-
Adana, Turquie (Türkiye), 01130
- Acibadem Adana Hastanesi
-
Adana, Turquie (Türkiye), 01130
- Acıbadem Adana Hastanesi-Hematoloji
-
Izmir, Turquie (Türkiye), 35100
- Ege Universitesi Tip Fakultesi
-
Izmir, Turquie (Türkiye), 35100
- Ege Üniversitesi Hastanesi- Hematoloji
-
Samsun, Turquie (Türkiye), 55139
- Ondokuz Mayis University Medical Faculty Ped. Haematology
-
Samsun, Turquie (Türkiye), 55139
- Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
-
-
Beşevler/Ankara
-
Ankara, Beşevler/Ankara, Turquie (Türkiye), 06500
- Gazi University
-
Ankara, Beşevler/Ankara, Turquie (Türkiye), 06500
- Gazi Üniversitesi Hastanesi- Hematoloji
-
-
-
-
California
-
San Diego, California, États-Unis, 92123
- Rady Childrens Hosp San Diego
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- University of Colorado Hospital
-
-
Florida
-
Orlando, Florida, États-Unis, 32806
- Arnold Palmer Children's Hospital
-
Orlando, Florida, États-Unis, 32827
- Nemours Child Orlando Hem/Onc.
-
-
Georgia
-
Augusta, Georgia, États-Unis, 30912
- Augusta Univ/Childrens Hosp-GA
-
Savannah, Georgia, États-Unis, 31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Childrens Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46260
- Indiana Hemophilia-Thromb Ctr
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Clinic Foundation
-
New Orleans, Louisiana, États-Unis, 70118
- Children's Hosp-New Orleans
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64108
- The Children's Mercy Hospital
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68114
- Children's Nebraska
-
-
North Carolina
-
Greenville, North Carolina, États-Unis, 27834
- ECU Sickle Cell Comp Clinic
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19134
- St Christopher Hosp for Child
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Fort Worth, Texas, États-Unis, 76104
- Cook Children's Hospital-Hematology-Oncology
-
Houston, Texas, États-Unis, 77030
- Texas Children's Hospital_Houston
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22908
- Pediatrics Hematology/Oncology Clinic Battle Building
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
-
Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.
-
For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.
-
For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)
- Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
-
For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)
- Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
- Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
-
For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention or related products.
- Known inherited or acquired coagulation disorder other than congenital haemophilia.
- Ongoing or planned Immune Tolerance Induction treatment.
- History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Concizumab-naïve patients
Concizumab-naïve participants below 12 years of age at the time of consent/assent |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
|
Expérimental: Patients coming from compassionate use
Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807 |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of patient(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: Week 32
|
Measured in ng/mL |
Week 32
|
|
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: Week 32
|
Measured in nM |
Week 32
|
|
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Délai: Week 32
|
Measured in ng/mL |
Week 32
|
|
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Délai: Prior to the concizumab administration at week 20
|
Measured in ng/mL |
Prior to the concizumab administration at week 20
|
|
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
|
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Délai: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng*hr/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies génétiques, innées
- Maladies hématologiques
- Troubles de la coagulation sanguine
- Troubles hémorragiques
- Troubles de la coagulation sanguine, héréditaires
- Troubles des protéines de la coagulation
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies hémiques et lymphatiques
- Hémophilie A
- concizumab
Autres numéros d'identification d'étude
- NN7415-4616
- U1111-1247-7330 (Autre identifiant: World Health Organization (WHO))
- 2020-000504-11 (Numéro EudraCT)
- jRCT2031220097 (Identificateur de registre: JAPIC)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .